Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 33.3%Low 1 · 33.3%Moderate 1 · 33.3%High 0 · 0%

Neurotoxicity · women with recurrent epithelial ovarian cancer

175 mg/m2 paclitaxel probably leads to lower neurotoxicity compared with 250 mg/m2 paclitaxel (moderate certainty).

1 finding from 1 review

Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
RR 0.41 [0.21, 0.8]
1 study · 330 participants
Moderate

Neurotoxicity · women with recurrent epithelial ovarian cancer

135 mg/m2 paclitaxel showed no clear difference in neurotoxicity compared with 175 mg/m2 paclitaxel (low certainty).

1 finding from 1 review

Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
RR 0.19 [0.01, 3.99]
1 study · 391 participants
Low

Neurotoxicity · women with recurrent epithelial ovarian cancer

It is very uncertain whether weekly paclitaxel changes neurotoxicity compared with three‐weekly paclitaxel (very low certainty).

1 finding from 1 review

Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
RR 0.53 [0.19, 1.48]
2 studies · 260 participants
Very low